Company Overview and News

7
Rounds Report: Alpine Immune Sciences Broke The Trend In A Down Market

2018-07-18 seekingalpha
The overall bioscience market started off Monday on a pessimistic note. Nevertheless, several equities under our coverage still posted some gains for investors.
FMAGX GILD ESPR KITE IBB XBI ALPN

69
Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

2018-07-17 seekingalpha
Gilead (GILD) has annual revenues in the HIV class of drugs of over $14.2 billion, and only has one phase 3 drug in clinical trials to protect its dominance in this category. GILD’s $14 billion annual income stream could be in jeopardy, because they are literally one drug approval away from an armageddon they admit in their 10-K is coming. A small competitor, Cytodyn Inc. (OTCQB:CYDY), has been struggling for over a decade to get PRO 140 approved as a salvage therapy to drug resistant HIV patients.
CYDY AMGN GILD JNJ GSK KITE PFE GSK PGNX

24
Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

2018-07-11 globenewswire
NEW YORK and MELBOURNE, Australia, July 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board.
MEOBF CELGZ GILD MSB CELG MESO KITE

8
Gilead Q2 Results Could Initiate A Rally

2018-07-09 seekingalpha
Last winter I wrote the glum, only somewhat tongue-in-cheek, Gilead Sciences: Going Down When It Should Go Up. The day before it was published, Gilead Sciences (NASDAQ:GILD) closed at $72.70. On July 6, 2018, it closed at $75.21, but it has been as low as $64.27 in the interim. Gilead seems to have become the Rodney Dangerfield of large biotech companies: it don't get no respect, despite its enormous revenues and profits.
GILD BIIB GLPG KITE

24
Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell.
TPIV FGEN GALTW GLPG GALTU LJPC GLPG KITE PFSCF GALT

6
Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors

2018-07-05 globenewswire
MONTREAL, July 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the appointment of accomplished industry executive, Shawn Cline Tomasello, to the company’s board of directors.
CELGZ CELG KITE CMTA DPLO

5
Clementia nomme Shawn Tomasello, une cadre chevronnée de l’industrie, au sein de son conseil d’administration

2018-07-05 globenewswire
MONTRÉAL, 05 juill. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles osseux ultra-rares et d’autres maladies, a annoncé aujourd’hui la nomination de Shawn Cline Tomasello, une cadre chevronnée de l’industrie, à son conseil d’administration.
CELGZ CELG KITE CMTA DPLO

21
BrainStorm Expands Leadership Team on Heels of Right-to-Try Controversy

2018-06-28 biospace
The senior leadership team at Israel-based BrainStorm Cell Therapeutics Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.
JUNO BCLI KITE

29
Movers and Shakers: Biotech Leadership Changes for June 25

2018-06-26 biospace
The week of June 18 to June 22 was bookended by big hiring announcement in the pharma industry. It began with a former Cowen analyst being tapped as chief financial officer of startup Allogene and ended with the retirement announcement of the group worldwide chairman at Johnson & Johnson.
OMED 506285 ELOX KITE BYRQY BAYERCROP SVOND

95
Atara Biotherapeutics: 2 New Catalysts To Fuel Further Growth

2018-06-22 seekingalpha
Company recently deepened its research relationship with Memorial Sloan Kettering; partnered with TrakCel for Atara MatchMe; completed the Atara T Cell Operations & Manufacturing facility; and strengthened the balance sheet.
AMGN ATRA GILD KITE

21
Israel's UroGen to start mid-stage bladder cancer trial

2018-06-21 channelnewsasia
RAANANA, Israel: Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.
GILD URGN KITE

20
Allogene Expands Leadership Team, Taps Cowen Senior Analyst as New CFO

2018-06-19 biospace
Since Allogene Therapeutics launched in April the company has been rapidly expanding its leadership team as it drives forward with a mission of developing allogeneic CAR-T therapies. The latest company addition is new Chief Financial Officer Eric Schmidt.
GILD KITE

518
20 Long-Term Value Stocks With Hulking Upside

2018-06-14 investorplace
In the value stocks versus growth stocks tug-of-war, growth stocks have been the unequivocal winner for the past several years. But that may change soon.
SIG TIF TWX SKX WMT KR AMZN NKE AAPL DKS KSS KITE INTC DIS GE GEC AMC GILD M TWC FOSL SIG TGT T MU ZUMZ GNE GPS NTAP FL

32
ITUS Corp. (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy

2018-06-12 accesswire
CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. However, thanks to incredible advances in the areas of cancer diagnostics and immunotherapy, the mortality rate may change drastically ahead.
ITUS GILD JUNO KITE

53
What’s a stock worth in the new economy?

2018-06-11 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
LMT NKE GILD GSK KITE ADSK GSK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 49803L109